AGEL Stredomoravska nemocnicni a.s.
- Address
- Dvorakova 75, 751 52 Přerov, Czechia
AGEL Stredomoravska nemocnicni a.s. - Cardiovascular Disease Research Center
AGEL Stredomoravska nemocnicni a.s. is a specialized cardiovascular research facility focused on advancing therapeutic interventions for patients with complex cardiovascular conditions. The center demonstrates particular expertise in evaluating novel pharmacological approaches for heart failure with renal impairment and atherosclerotic cardiovascular disease, conducting large-scale Phase III trials that assess both disease progression and major cardiovascular outcomes.
- Heart failure therapeutics combined with chronic kidney disease management
- Lipoprotein(a) modulation for cardiovascular event prevention
- LDL-cholesterol lowering strategies in established atherosclerotic disease
The research center participates in multinational trials examining cutting-edge interventions including mineralocorticoid receptor antagonist combinations, antisense oligonucleotide therapies for lipid management, and siRNA-based treatments targeting cholesterol reduction. Their clinical trial portfolio emphasizes prevention of major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarction, stroke, and urgent coronary revascularization in high-risk patient populations with established cardiovascular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novartis Pharma AG1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in AGEL Stredomoravska nemocnicni a.s.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Balcinrenone and Dapagliflozin on Cardiovascular Outcomes in Heart Failure Patients with Renal Impairment: A Phase III Randomized, Double-Blind Study | AstraZeneca AB | Phase III | Recruiting | Jul 2024 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pelacarsen | 2 | Unknown | 2020-03-06 | 2026-05-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.